1d8f

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /> <applet load="1d8f" size="450" color="white" frame="true" align="right" spinBox="true" caption="1d8f, resolution 2.4&Aring;" /> '''CRYSTAL STRUCTURE OF...)
Line 1: Line 1:
-
[[Image:1d8f.gif|left|200px]]<br />
+
[[Image:1d8f.gif|left|200px]]<br /><applet load="1d8f" size="350" color="white" frame="true" align="right" spinBox="true"
-
<applet load="1d8f" size="450" color="white" frame="true" align="right" spinBox="true"
+
caption="1d8f, resolution 2.4&Aring;" />
caption="1d8f, resolution 2.4&Aring;" />
'''CRYSTAL STRUCTURE OF MMP3 COMPLEXED WITH A PIPERAZINE BASED INHIBITOR.'''<br />
'''CRYSTAL STRUCTURE OF MMP3 COMPLEXED WITH A PIPERAZINE BASED INHIBITOR.'''<br />
==Overview==
==Overview==
-
A new generation of cyclic matrix metalloproteinase (MMP) inhibitors, derived from dl-piperazinecarboxylic acid has been described. The design, involves: incorporation of hydroxamic acid as the bidentate chelating, agent for catalytic Zn(2+), placement of a sulfonamide group at the, 1N-position of the piperazine ring to fill the S1' pocket of the enzyme, and finally attachment of diverse functional groups at the 4N-position to, optimize potency and peroral absorption. A unique combination of all three, elements produced inhibitor 20 with high affinity for MMPs 1, 3, 9, and 13, (24, 18, 1.9, and 1.3 nM, respectively). X-ray crystallography data, obtained for MMP-3 cocrystallized with 20 gave detailed information on key, binding interactions defining an overall scaffold geometry for, piperazine-based MMP inhibitors.
+
A new generation of cyclic matrix metalloproteinase (MMP) inhibitors derived from dl-piperazinecarboxylic acid has been described. The design involves: incorporation of hydroxamic acid as the bidentate chelating agent for catalytic Zn(2+), placement of a sulfonamide group at the 1N-position of the piperazine ring to fill the S1' pocket of the enzyme, and finally attachment of diverse functional groups at the 4N-position to optimize potency and peroral absorption. A unique combination of all three elements produced inhibitor 20 with high affinity for MMPs 1, 3, 9, and 13 (24, 18, 1.9, and 1.3 nM, respectively). X-ray crystallography data obtained for MMP-3 cocrystallized with 20 gave detailed information on key binding interactions defining an overall scaffold geometry for piperazine-based MMP inhibitors.
==Disease==
==Disease==
Line 11: Line 10:
==About this Structure==
==About this Structure==
-
1D8F is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with ZN, CA and SPI as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Stromelysin_1 Stromelysin 1], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.24.17 3.4.24.17] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1D8F OCA].
+
1D8F is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=ZN:'>ZN</scene>, <scene name='pdbligand=CA:'>CA</scene> and <scene name='pdbligand=SPI:'>SPI</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Stromelysin_1 Stromelysin 1], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.24.17 3.4.24.17] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1D8F OCA].
==Reference==
==Reference==
Line 18: Line 17:
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Stromelysin 1]]
[[Category: Stromelysin 1]]
-
[[Category: Almstead, N.G.]]
+
[[Category: Almstead, N G.]]
-
[[Category: Anastasio, M.V.]]
+
[[Category: Anastasio, M V.]]
-
[[Category: Chen, L.Y.]]
+
[[Category: Chen, L Y.]]
-
[[Category: Cheng, M.Y.]]
+
[[Category: Cheng, M Y.]]
[[Category: De, B.]]
[[Category: De, B.]]
-
[[Category: McPhail, S.J.]]
+
[[Category: McPhail, S J.]]
-
[[Category: Natchus, M.G.]]
+
[[Category: Natchus, M G.]]
[[Category: Pikul, S.]]
[[Category: Pikul, S.]]
-
[[Category: Snider, C.E.]]
+
[[Category: Snider, C E.]]
-
[[Category: Taiwo, Y.O.]]
+
[[Category: Taiwo, Y O.]]
[[Category: CA]]
[[Category: CA]]
[[Category: SPI]]
[[Category: SPI]]
Line 35: Line 34:
[[Category: zinc protease]]
[[Category: zinc protease]]
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 16:30:20 2007''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 12:14:05 2008''

Revision as of 10:14, 21 February 2008


1d8f, resolution 2.4Å

Drag the structure with the mouse to rotate

CRYSTAL STRUCTURE OF MMP3 COMPLEXED WITH A PIPERAZINE BASED INHIBITOR.

Contents

Overview

A new generation of cyclic matrix metalloproteinase (MMP) inhibitors derived from dl-piperazinecarboxylic acid has been described. The design involves: incorporation of hydroxamic acid as the bidentate chelating agent for catalytic Zn(2+), placement of a sulfonamide group at the 1N-position of the piperazine ring to fill the S1' pocket of the enzyme, and finally attachment of diverse functional groups at the 4N-position to optimize potency and peroral absorption. A unique combination of all three elements produced inhibitor 20 with high affinity for MMPs 1, 3, 9, and 13 (24, 18, 1.9, and 1.3 nM, respectively). X-ray crystallography data obtained for MMP-3 cocrystallized with 20 gave detailed information on key binding interactions defining an overall scaffold geometry for piperazine-based MMP inhibitors.

Disease

Known diseases associated with this structure: Coronary heart disease, susceptibility to OMIM:[185250]

About this Structure

1D8F is a Single protein structure of sequence from Homo sapiens with , and as ligands. Active as Stromelysin 1, with EC number 3.4.24.17 Full crystallographic information is available from OCA.

Reference

Design and synthesis of piperazine-based matrix metalloproteinase inhibitors., Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S, J Med Chem. 2000 Feb 10;43(3):369-80. PMID:10669564

Page seeded by OCA on Thu Feb 21 12:14:05 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools